Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAB-Paclitaxel vs CEP in Thymoma Induction
NCT05816694Phase 2Not yet recruiting
- Start
- Apr 2023
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of paclitaxel in thymoma (2 arms). Primary endpoint: Overall Response Rate at 1 year. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
paclitaxel
03
Conditions
thymoma
Beyond the preview
Go deeper on NCT05816694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05816694.